Alastair M Graham

Suggest Changes
Learn More
WHAT IS KNOWN AND OBJECTIVE Navitoclax, a first-in-class small molecule Bcl-2 family inhibitor, is metabolized in vitro by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4. Drugs that(More)
  • 1